Developer docs
API playgroundTry for free, no card

Search company profiles

Minerva Neuroscience

Full company profile

uuid00063v7

Namestring
Minerva Neuroscience
Legal namestring
Minerva Neurosciences, Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing central nervous system (CNS) therapeutics, with its lead program, roluperidone (MIN-101), in a confirmatory Phase 3 trial for the negative symptoms of schizophrenia—an indication with no FDA-approved therapy. Roluperidone is a proprietary compound acting as a 5-HT2A and sigma-1 receptor antagonist, designed to address the cognitive and affective symptom domains that antipsychotics largely fail to treat. The company is also developing MIN-301, a preclinical neuregulin-1 (NRG-1)-based asset for Parkinson's disease.

The company was founded to build a CNS-focused pipeline and operates from Massachusetts with a small (1–10 employee) organization consistent with a lean clinical-stage structure. Beyond its active pipeline, Minerva retains a royalty interest in seltorexant, an orexin-2 receptor antagonist partnered with Royalty Pharma, which provides a non-dilutive, contingent upside stream.

Minerva is currently pre-revenue and does not commercialize any products. Its economic model rests on three pillars: (1) eventual commercial launch of roluperidone in the U.S. and Europe, likely via specialty CNS channels targeting psychiatrists and high-volume schizophrenia prescribers; (2) selective out-licensing or partnership economics for MIN-301 if it advances; and (3) royalty income from seltorexant if approved by its partner. Capital for development has come primarily from equity issuance, most recently a $200 million private placement tranche structure.

Short descriptiontext

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing CNS therapies, with lead candidate roluperidone in Phase 3 trials for negative symptoms of schizophrenia. It also holds a preclinical Parkinson's asset and a royalty interest in seltorexant.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical stage biopharmaceutical, CNS therapeutics, schizophrenia treatment, central nervous system drugs, neurological drug development
Industry1 code
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
CNS Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Seltorexant Royalties
TypeLicensing Royalties
Description

Following opt-out from joint development with Janssen in 2020, Minerva is entitled to collect royalties in mid-single digits on potential future sales of seltorexant worldwide in certain indications. Royalty Pharma acquired this royalty interest in January 2021 for $60M upfront plus up to $95M in additional milestone payments.

minervaneurosciences.com
2Roluperidone Commercial Sales (Future)
TypeOne Time License
Description

Potential future commercial revenue from roluperidone for treating negative symptoms of schizophrenia. If approved, roluperidone would be the first and only FDA-approved therapy specifically targeting this patient population. Peak U.S. sales projected at approximately $1.9 billion by 2034.

biospace.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing a portfolio of product candidates to treat central nervous system (CNS) diseases. Its lead candidate, roluperidone (MIN-101), is in Phase 3 development for the treatment of negative symptoms of schizophrenia, with additional preclinical candidate MIN-301 targeting Parkinson's disease and a retained royalty interest in seltorexant.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Peak U.S. sales projected at approximately $1.9 billion by 2034 with 65% probability of approval and 20% peak market penetration in the 650,000-patient market
+2 more records
Product overview1 text field

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing a portfolio of central nervous system disorder treatments. The company's core pipeline consists of three product candidates: Roluperidone (MIN-101) for negative symptoms of schizophrenia (Phase 3 stage), MIN-301 for Parkinson's disease (preclinical stage), and Seltorexant for insomnia/MDD (royalty interest only, currently in Phase 3 by Janssen). The company is preparing for potential FDA approval and commercial launch of roluperidone, which would be the first treatment specifically targeting negative symptoms of schizophrenia in the United States.

Product and service3 records
1Roluperidone (MIN-101)
CategorySchizophrenia Therapeutics
Description

Roluperidone is a novel compound that blocks serotonin (5-HT2A), sigma2, and alpha-1A adrenergic receptors. It is being developed for the treatment of negative symptoms in patients with schizophrenia, addressing symptoms such as asociality, anhedonia, alogia, avolition, and blunted affect. It also promotes slow wave sleep disrupted in schizophrenia patients.

2MIN-301
CategoryParkinson's Disease Therapeutics
Description

MIN-301 is a recombinant form of neuregulin-1β1 protein in preclinical development for the treatment of Parkinson's disease. It has shown potential to slow disease onset and restore brain tissue damage by activating ErbB4 receptors, with potential to restore motor function and produce positive cognitive effects in preclinical models.

3Seltorexant (Royalty Interest)
CategoryRoyalty Stream / CNS Asset
Description

Seltorexant is an insomnia and major depressive disorder (MDD) treatment candidate originally co-developed with Janssen. Minerva no longer develops the asset directly but retains royalty rights in mid-single digits on potential future sales worldwide in certain indications.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Previously co-developed seltorexant with Janssen for insomnia and MDD. Minerva exercised its right to opt out of joint development in 2020, retaining royalty rights in mid-single digits on future sales.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CNS-focused biopharma with Caplyta (lumateperone) approved for schizophrenia and bipolar depression; most directly comparable late-stage CNS specialty pharma competitor with overlapping schizophrenia commercial strategy.

TypeDirect peer
Description

Developed xanomeline + trospium for schizophrenia targeting muscarinic receptors; now part of BMS. Most direct mechanistic alternative in the negative-symptom/adjacent schizophrenia space, now with deep commercial resources.

TypeDirect peer
Description

CNS pipeline including emraclidine (M4 muscarinic agonist) in schizophrenia Phase 3; acquired by AbbVie in 2024. Comparable CNS specialty pharma with overlapping schizophrenia development and AbbVie-backed commercialization.

TypeDirect peer
Description

Established CNS biopharma with ARISTADA (aripiprazole lauroxil) for schizophrenia and Lybalvi (olanzapine/samidorphan). Direct competitor in the schizophrenia commercial market with existing specialty sales infrastructure.

TypeBroad incumbent
Description

Larger CNS specialty biopharma with NUPLAZID for Parkinson's-disease psychosis and a broader CNS pipeline; overlapping neurology/psychiatry therapeutic focus with comparable patient-targeting model.

TypeDirect peer
Description

CNS-focused commercial-stage biopharma with Auvelity (dextromethorphan/bupropion) for MDD and other CNS assets in development; comparable small-cap CNS specialty pharma with similar commercial launch profile.

TypeDirect peer
Description

CNS-focused biopharma developing therapies in depression and neurology; recently acquired by Biogen. Closely comparable CNS specialty R&D profile targeting high-unmet-need psychiatric and neurologic indications.

TypeEmerging player
Description

Clinical-stage CNS biopharma developing therapies for depression and schizophrenia with mechanism-diverse pipeline; comparable preclinical/early-clinical stage company targeting similar patient populations.

TypeEmerging player
Description

Clinical-stage biopharma with IGALMI (dexmedetomidine) approved for acute agitation in schizophrenia/bipolar and an AI-driven pipeline. Comparable small CNS specialty company targeting schizophrenia-related symptoms.

TypeBroad incumbent
Description

Established CNS incumbent with LATUDA (lurasidone) for schizophrenia and depression; broader psychiatry commercial portfolio. Comparable established CNS commercial organization with direct schizophrenia franchise overlap.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors23 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Minerva Neuroscience

CNS Therapeuticsminervaneurosciences.com

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing CNS therapies, with lead candidate roluperidone in Phase 3 trials for negative symptoms of schizophrenia. It also holds a preclinical Parkinson's asset and a royalty interest in seltorexant.

What Minerva Neuroscience does

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing central nervous system (CNS) therapeutics, with its lead program, roluperidone (MIN-101), in a confirmatory Phase 3 trial for the negative symptoms of schizophrenia—an indication with no FDA-approved therapy. Roluperidone is a proprietary compound acting as a 5-HT2A and sigma-1 receptor antagonist, designed to address the cognitive and affective symptom domains that antipsychotics largely fail to treat. The company is also developing MIN-301, a preclinical neuregulin-1 (NRG-1)-based asset for Parkinson's disease.

The company was founded to build a CNS-focused pipeline and operates from Massachusetts with a small (1–10 employee) organization consistent with a lean clinical-stage structure. Beyond its active pipeline, Minerva retains a royalty interest in seltorexant, an orexin-2 receptor antagonist partnered with Royalty Pharma, which provides a non-dilutive, contingent upside stream.

Minerva is currently pre-revenue and does not commercialize any products. Its economic model rests on three pillars: (1) eventual commercial launch of roluperidone in the U.S. and Europe, likely via specialty CNS channels targeting psychiatrists and high-volume schizophrenia prescribers; (2) selective out-licensing or partnership economics for MIN-301 if it advances; and (3) royalty income from seltorexant if approved by its partner. Capital for development has come primarily from equity issuance, most recently a $200 million private placement tranche structure.

Minerva Neuroscience firmographics

Firmographics
Name
Minerva Neuroscience
Legal name
Minerva Neurosciences, Inc.
Website
https://minervaneurosciences.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing CNS therapies, with lead candidate roluperidone in Phase 3 trials for negative symptoms of schizophrenia. It also holds a preclinical Parkinson's asset and a royalty interest in seltorexant.
Ownership category
akta.pro rank

Minerva Neuroscience industry classification

Industry
Product category
CNS Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical stage biopharmaceutical
  • CNS therapeutics
  • Schizophrenia treatment
  • Central nervous system drugs
  • Neurological drug development

Where Minerva Neuroscience is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Minerva Neuroscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Seltorexant Royalties: Following opt-out from joint development with Janssen in 2020, Minerva is entitled to collect royalties in mid-single digits on potential future sales of seltorexant worldwide in certain indications. Royalty Pharma acquired this royalty interest in January 2021 for $60M upfront plus up to $95M in additional milestone payments.
  2. Roluperidone Commercial Sales (Future): Potential future commercial revenue from roluperidone for treating negative symptoms of schizophrenia. If approved, roluperidone would be the first and only FDA-approved therapy specifically targeting this patient population. Peak U.S. sales projected at approximately $1.9 billion by 2034.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Minerva Neuroscience product offering

Product offering

Core offering

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing a portfolio of product candidates to treat central nervous system (CNS) diseases. Its lead candidate, roluperidone (MIN-101), is in Phase 3 development for the treatment of negative symptoms of schizophrenia, with additional preclinical candidate MIN-301 targeting Parkinson's disease and a retained royalty interest in seltorexant.

Product overview

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing a portfolio of central nervous system disorder treatments. The company's core pipeline consists of three product candidates: Roluperidone (MIN-101) for negative symptoms of schizophrenia (Phase 3 stage), MIN-301 for Parkinson's disease (preclinical stage), and Seltorexant for insomnia/MDD (royalty interest only, currently in Phase 3 by Janssen). The company is preparing for potential FDA approval and commercial launch of roluperidone, which would be the first treatment specifically targeting negative symptoms of schizophrenia in the United States.

Differentiator

Problem solved

Functional benefit

Products and services

  • Roluperidone (MIN-101) Roluperidone is a novel compound that blocks serotonin (5-HT2A), sigma2, and alpha-1A adrenergic receptors. It is being developed for the treatment of negative symptoms in patients with schizophrenia, addressing symptoms such as asociality, anhedonia, alogia, avolition, and blunted affect. It also promotes slow wave sleep disrupted in schizophrenia patients.
  • MIN-301 MIN-301 is a recombinant form of neuregulin-1β1 protein in preclinical development for the treatment of Parkinson's disease. It has shown potential to slow disease onset and restore brain tissue damage by activating ErbB4 receptors, with potential to restore motor function and produce positive cognitive effects in preclinical models.
  • Seltorexant (Royalty Interest) Seltorexant is an insomnia and major depressive disorder (MDD) treatment candidate originally co-developed with Janssen. Minerva no longer develops the asset directly but retains royalty rights in mid-single digits on potential future sales worldwide in certain indications.

Quantifiable outcome

  • Peak U.S. sales projected at approximately $1.9 billion by 2034 with 65% probability of approval and 20% peak market penetration in the 650,000-patient market
  • +2 more outcomes

Companies that use Minerva Neuroscience

Customer profile

Segments2 records

Ideal customer profiles2 records

Minerva Neuroscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Minerva Neuroscience partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Janssen Pharmaceutica NVcoreStrategic or Co-development Partner · 1 January 2020Previously co-developed seltorexant with Janssen for insomnia and MDD. Minerva exercised its right to opt out of joint development in 2020, retaining royalty rights in mid-single digits on future sales.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Minerva Neuroscience competitors and assessment

Company assessment

Direct peers

  • Intra-Cellular Therapies: CNS-focused biopharma with Caplyta (lumateperone) approved for schizophrenia and bipolar depression; most directly comparable late-stage CNS specialty pharma competitor with overlapping schizophrenia commercial strategy.
  • Karuna Therapeutics (Bristol Myers Squibb): Developed xanomeline + trospium for schizophrenia targeting muscarinic receptors; now part of BMS. Most direct mechanistic alternative in the negative-symptom/adjacent schizophrenia space, now with deep commercial resources.
  • Cerevel Therapeutics (AbbVie): CNS pipeline including emraclidine (M4 muscarinic agonist) in schizophrenia Phase 3; acquired by AbbVie in 2024. Comparable CNS specialty pharma with overlapping schizophrenia development and AbbVie-backed commercialization.
  • Alkermes: Established CNS biopharma with ARISTADA (aripiprazole lauroxil) for schizophrenia and Lybalvi (olanzapine/samidorphan). Direct competitor in the schizophrenia commercial market with existing specialty sales infrastructure.
  • Axsome Therapeutics: CNS-focused commercial-stage biopharma with Auvelity (dextromethorphan/bupropion) for MDD and other CNS assets in development; comparable small-cap CNS specialty pharma with similar commercial launch profile.
  • Sage Therapeutics (now part of Biogen): CNS-focused biopharma developing therapies in depression and neurology; recently acquired by Biogen. Closely comparable CNS specialty R&D profile targeting high-unmet-need psychiatric and neurologic indications.

Broad incumbents

  • Acadia Pharmaceuticals: Larger CNS specialty biopharma with NUPLAZID for Parkinson's-disease psychosis and a broader CNS pipeline; overlapping neurology/psychiatry therapeutic focus with comparable patient-targeting model.
  • Sumitomo Pharma America (formerly Sunovion/Latuda): Established CNS incumbent with LATUDA (lurasidone) for schizophrenia and depression; broader psychiatry commercial portfolio. Comparable established CNS commercial organization with direct schizophrenia franchise overlap.

Emerging players

  • Neumora Therapeutics: Clinical-stage CNS biopharma developing therapies for depression and schizophrenia with mechanism-diverse pipeline; comparable preclinical/early-clinical stage company targeting similar patient populations.
  • BioXcel Therapeutics: Clinical-stage biopharma with IGALMI (dexmedetomidine) approved for acute agitation in schizophrenia/bipolar and an AI-driven pipeline. Comparable small CNS specialty company targeting schizophrenia-related symptoms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks7 records

Key highlights7 records

Customer concentration

Minerva Neuroscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Minerva Neuroscience leadership team

Management profile

Number of profiles

Profiles5 records

Minerva Neuroscience funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Minerva Neuroscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minerva Neuroscience

What does Minerva Neuroscience do?

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing a portfolio of product candidates to treat central nervous system (CNS) diseases. Its lead candidate, roluperidone (MIN-101), is in Phase 3 development for the treatment of negative symptoms of schizophrenia, with additional preclinical candidate MIN-301 targeting Parkinson's disease and a retained royalty interest in seltorexant.

Is Minerva Neuroscience a public or private company?

Minerva Neuroscience is a public company. It is classified as public and is currently operating.

When was Minerva Neuroscience founded?

Minerva Neuroscience was founded in 2014. It employs 1 to 10 people.

Where is Minerva Neuroscience based?

Minerva Neuroscience is headquartered in Waltham, United States, in the North America region.

How does Minerva Neuroscience make money?

Two revenue lines are on record. Seltorexant Royalties are the primary driver. The others are roluperidone Commercial Sales (Future).

Who are Minerva Neuroscience's main competitors?

Direct peers on record are Intra-Cellular Therapies, Karuna Therapeutics (Bristol Myers Squibb), Cerevel Therapeutics (AbbVie), Alkermes, Axsome Therapeutics and Sage Therapeutics (now part of Biogen). Broad incumbents are Acadia Pharmaceuticals and Sumitomo Pharma America (formerly Sunovion/Latuda). Emerging players are Neumora Therapeutics and BioXcel Therapeutics.

Does Minerva Neuroscience have an API?

No public API is recorded for Minerva Neuroscience.

What industry is Minerva Neuroscience in?

Minerva Neuroscience's product category is CNS Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comMinerva at Jefferies Global Healthcare Conference: roluperidone push advancesMinerva presented roluperidone, an experimental schizophrenia treatment for negative symptoms, at the Jefferies Global Healthcare Conference. The company's Phase III trial data is expected in 2027-2028, and management said the $200 million raised last year is insufficient for full commercialization. The drug's regulatory path has aligned with the FDA after a public meeting.TradingViewMinerva Neurosciences Revises Roluperidone Transcript, Cautions FDA Approval Is Not AssuredMinerva Neurosciences issued a revised roluperidone event transcript, clarifying that positive Phase A results do not assure FDA approval. The company stated approval predictions were personal opinions, not commitments, and any NDA resubmission depends on C19 results and further assessment. Minerva remains committed to completing Phase B and plans to review Phase A results with the FDA.Seeking AlphaMinerva Neurosciences, Inc. (NERV) Discusses Roluperidone for Negative Symptoms of Schizophrenia TranscriptMinerva Neurosciences CEO Rémy Luthringer presented roluperidone for negative symptoms of schizophrenia on a conference call, noting the drug offers hope after 70 years of research. He highlighted the company's public status and invited questions from analysts.TradingViewNERV: A warrant revaluation gain drove reported Q3 profit as roluperidone’s confirmatory trial advancedMinerva Neurosciences reported Q3 GAAP net income of $100.7 million, driven by a $109.6 million non-cash warrant revaluation gain, while adjusted net loss was $5.6 million. The company's confirmatory trial for roluperidone is underway, with topline efficacy results expected in H2 2027, and $77.0 million in cash and investments is expected to fund commitments for at least 12 months.MarketScreenerMinerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Minerva Neurosciences reported Q3 2026 net income of $100.75 million, up from a $2.74 million loss a year earlier. For the nine months, net loss narrowed to $7.19 million from $9.76 million. The company is developing roluperidone for schizophrenia and MIN-301 for Parkinson's disease.FinanzNachrichten.deNo Brainer Club trotzt dem Markt: +33% Tradingprofit innerhalb 24 HandelsstundenNo Brainer Club members earned a +33% trading profit within 24 trading hours on two biotech rebound trades. The gains came from aTyr Pharma and Minerva Neurosciences, achieved through precise timing and consistent risk management by chief analyst Maximilian.American Banking and Market NewsMinerva Neurosciences, Inc (NERV) – What Are Investment Firms Thinking About This Stock?Minerva Neurosciences shares have an average analyst rating of "Hold" with a twelve-month price target of $10.33. The company reported a quarterly loss of $0.14 per share, beating estimates, and institutional investors own 34.56% of the stock.MarketBeatMinerva Neurosciences (NASDAQ:NERV) Cut to "Sell" at Wall Street ZenWall Street Zen downgraded Minerva Neurosciences from Hold to Sell on Saturday. The stock opened at $2.32, with an average analyst rating of Hold and a consensus target price of $10.33. The company reported a quarterly loss of $0.14 per share, beating estimates.American Banking and Market NewsMinerva Neurosciences (NASDAQ:NERV) Rating Lowered to Sell at Wall Street ZenWall Street Zen downgraded Minerva Neurosciences from Hold to Sell on Saturday. The company's consensus rating remains Hold with an average target price of $10.33, and shares opened at $2.32. Analysts expect a fiscal-year EPS of -$0.73.MarketBeatMinerva Neurosciences (NERV) Set to Announce Quarterly Earnings on WednesdayMinerva Neurosciences is set to announce Q3 2026 earnings on Wednesday, with analysts expecting a loss of $0.14 per share. The company previously reported a $0.14 loss, beating the consensus estimate of $0.19. Analysts have an average "Hold" rating with a consensus target price of $10.33.